261 related articles for article (PubMed ID: 17347975)
1. L-Propionyl carnitine, homocysteine and S-adenosylhomocysteine in hemodialysis.
Perna AF; Acanfora F; Satta E; Lombardi C; Capasso R; Ingrosso D; De Santo NG
J Nephrol; 2007; 20(1):63-5. PubMed ID: 17347975
[TBL] [Abstract][Full Text] [Related]
2. Elevated homocysteine levels in patients with end-stage renal disease.
Nair AP; Nemirovsky D; Kim M; Geer EB; Farkouh ME; Winston J; Halperin JL; Robbins MJ
Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review.
Ferrari R; Merli E; Cicchitelli G; Mele D; Fucili A; Ceconi C
Ann N Y Acad Sci; 2004 Nov; 1033():79-91. PubMed ID: 15591005
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients.
Valli A; Carrero JJ; Qureshi AR; Garibotto G; Bárány P; Axelsson J; Lindholm B; Stenvinkel P; Anderstam B; Suliman ME
Clin Chim Acta; 2008 Sep; 395(1-2):106-10. PubMed ID: 18565329
[TBL] [Abstract][Full Text] [Related]
5. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease.
Signorelli SS; Fatuzzo P; Rapisarda F; Neri S; Ferrante M; Oliveri Conti G; Fallico R; Di Pino L; Pennisi G; Celotta G; Anzaldi M
Kidney Blood Press Res; 2006; 29(2):100-7. PubMed ID: 16809937
[TBL] [Abstract][Full Text] [Related]
6. Interrelations between plasma homocysteine and intracellular S-adenosylhomocysteine.
Fu W; Dudman NP; Perry MA; Young K; Wang XL
Biochem Biophys Res Commun; 2000 Apr; 271(1):47-53. PubMed ID: 10777679
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL
Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405
[TBL] [Abstract][Full Text] [Related]
8. Homocysteine clearance and methylation flux rates in health and end-stage renal disease: association with S-adenosylhomocysteine.
Stam F; van Guldener C; ter Wee PM; Kulik W; Smith DE; Jakobs C; Stehouwer CD; de Meer K
Am J Physiol Renal Physiol; 2004 Aug; 287(2):F215-23. PubMed ID: 15271686
[TBL] [Abstract][Full Text] [Related]
9. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
Heinz J; Kropf S; Luley C; Dierkes J
Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
[TBL] [Abstract][Full Text] [Related]
10. L-carnitine supplementation and adipokines in patients with end-stage renal disease on regular hemodialysis.
Csiky B; Nyul Z; Tóth G; Wittmann I; Melegh B; Rauh M; Rascher W; Sulyok E
Exp Clin Endocrinol Diabetes; 2010 Nov; 118(10):735-40. PubMed ID: 20658442
[TBL] [Abstract][Full Text] [Related]
11. The effect of mesna on plasma total homocysteine concentration in hemodialysis patients.
Urquhart BL; Freeman DJ; Spence JD; House AA
Am J Kidney Dis; 2007 Jan; 49(1):109-17. PubMed ID: 17185151
[TBL] [Abstract][Full Text] [Related]
12. [Alteration of homocysteine before and after hemodialysis in chronic hemodialysis patients].
Wang HT; Peng YM; Liu H
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):266-8. PubMed ID: 14653086
[TBL] [Abstract][Full Text] [Related]
13. [Secondary L-carnitine deficiency in chronic hemodialysis patients].
Achenbach H; Würzberger G; Seim H; Löster H; Strauss B
Z Gesamte Inn Med; 1989 Jan; 44(1):18-22. PubMed ID: 2711712
[TBL] [Abstract][Full Text] [Related]
14. The effects of L-carnitine therapy on respiratory function tests in chronic hemodialysis patients.
Bavbek N; Akay H; Uz B; Uz E; Turgut F; Kanbay M; Senes M; Akcay A; Duranay M
Ren Fail; 2010 Jan; 32(2):157-61. PubMed ID: 20199175
[TBL] [Abstract][Full Text] [Related]
15. Adverse effects of hyperhomocysteinemia and their management by folic acid.
Perna AF; De Santo NG; Ingrosso D
Miner Electrolyte Metab; 1997; 23(3-6):174-8. PubMed ID: 9387111
[TBL] [Abstract][Full Text] [Related]
16. Effects of L-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients.
Hakeshzadeh F; Tabibi H; Ahmadinejad M; Malakoutian T; Hedayati M
Ren Fail; 2010; 32(9):1109-14. PubMed ID: 20863217
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effect of intravenous l-carnitine on quality of life in chronic hemodialysis patients.
Semeniuk J; Shalansky KF; Taylor N; Jastrzebski J; Cameron EC
Clin Nephrol; 2000 Dec; 54(6):470-7. PubMed ID: 11140808
[TBL] [Abstract][Full Text] [Related]
18. Effects of L-carnitine on leukocyte function and viability in hemodialysis patients: A double-blind randomized trial.
Thomas S; Fischer FP; Mettang T; Pauli-Magnus C; Weber J; Kuhlmann U
Am J Kidney Dis; 1999 Oct; 34(4):678-87. PubMed ID: 10516349
[TBL] [Abstract][Full Text] [Related]
19. Homocysteine, S-adenosylmethionine and S-adenosylhomocysteine are associated with retinal microvascular abnormalities: the Hoorn Study.
Van Hecke MV; Dekker JM; Nijpels G; Teerlink T; Jakobs C; Stolk RP; Heine RJ; Bouter LM; Polak BC; Stehouwer CD
Clin Sci (Lond); 2008 Apr; 114(7):479-87. PubMed ID: 17956228
[TBL] [Abstract][Full Text] [Related]
20. Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients.
Sakurauchi Y; Matsumoto Y; Shinzato T; Takai I; Nakamura Y; Sato M; Nakai S; Miwa M; Morita H; Miwa T; Amano I; Maeda K
Am J Kidney Dis; 1998 Aug; 32(2):258-64. PubMed ID: 9708610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
